The medical technology company Eckert & Ziegler has experienced a double-digit sales increase of 11.2 percent to EUR 21.8 million in the first nine months of fiscal year 2012. However, the profit of EUR 1.04 million fell to EUR 0.9 million. EBIT fell by 3.6 percent from EUR 2.28 million to EUR 2.12 million.
The growth in sales of the company’s core business of selling cancer treatment primarily of radiotherapeutic implants contributed to the permanent brachytherapy and income from the temporary brachytherapy equipment.
[ilink url=“http://www.bebig.eu/press/press_releases.html?user_hugin_pi1%5BCMD%5D=singleView&user_hugin_pi1%5BshowUid%5D=1655012&user_hugin_pi1%5Bpage%5D=0&cHash=061e0c02b51ca8d40a771292f7ab78d5″] Link zur Quelle (Eckert & Ziegler)[/ilink]